June 23, 2016
When PolyCore Therapeutics, a Drexel spinout, began developing a breakthrough drug to manage the symptoms of Parkinson’s Disease, CEO Jim Harris and Sandhya Kortagere (pictured) quickly realized that they could hasten their journey to funding via the Science Center’s newest commercialization program, Phase 1 Ventures.
Read More